FindTrial
Sign In

The effect of sugammadex for rocuronium-induced neuromuscular blockade in patients with severe renal impairment

Efficacy and safety of sugammadex for rocuronium-induced neuromuscular blockade in patients with severe renal impairment: A systematic review of observational studies - sugammadex for patient with severe renal impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041735
Enrollment
Unknown
Registered
2021-06-01
Start date
2020-09-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A systematic review of observational studies

Interventions

None listed

Sponsors

Korea university Guro hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients aged more than18 years scheduled to undergo a surgical procedure using rocuronium for neuromuscular blockade (NMB) and sugammadex for NMB reversal during general anesthesia The relevant case-control studies with sugammadex treatment to patients with severe renal impairment (group R) compared to patients with normal renal function (group N).

Exclusion criteria

Exclusion criteria: Neostigmine treatment study, pediatrics study

Design outcomes

Primary

MeasureTime frame
The primary outcome is mean times taken to reach a train of four ratio more than 0.9, 0.8 and 0.7.—

Countries

Asia(except Japan)

Contacts

Public ContactYoung Ju Won

Korea university Guro hospital Department of the anesthesia and pain medicine

moma2@naver.com082-2-2626-1437

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026